On this page
Back to topKailera Therapeutics KLRA
Kailera Therapeutics listed on Nasdaq on 17 Apr 2026 and is not in the S&P 500. It is worth $1.5 billion. Its price history starts on 17 Apr 2026. 8 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 8 other officers are on file. At 30 Jun 2026, Bain Capital Investors was its largest institutional holder, with 20.3% of the company.
- CEO
- Ronald C. Renaud Jr.
- Listed
- 17 Apr 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Waltham, MA
- Market cap
- $1.5B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Kailera Therapeutics' market cap since April 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.7B |
Download Kailera Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 17 Apr 2026.
Board and leadership
Board and officers
2 people here also hold roles at other S&P 500 companies.
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (8) | |
| Ronald C. Renaud Jr.CEO & President | |
| Frank ClyburnDirectorAlso at Cencora | |
| Christopher HiteDirector | |
| Andrew T. KaplanDirector | |
| Adam KoppelDirector | |
| Yuting LiuDirector | |
| Martin MackayDirectorAlso at Charles River Laboratories | |
| John F. MilliganDirector | |
| Officers (8) | |
| Douglas W. PaganChief Financial OfficerLast filed 20 Apr 2026 | |
| Scott AkamineChief Legal OfficerLast filed 20 Apr 2026 | |
| Paul D. BurgessChief Operating Officer & Chief Business OfficerLast filed 20 Apr 2026 | |
| Paula CloghessyChief People OfficerLast filed 20 Apr 2026 | |
| Jamie Beth ColemanChief Commercial OfficerLast filed 20 Apr 2026 | |
| Nur NicholsonChief Technology OfficerLast filed 9 Sep 2026 | |
| Kathleen TregoningChief Corporate Affairs OfficerLast filed 8 Jul 2026 | |
| Scott M. WassermanChief Medical OfficerLast filed 20 Apr 2026 | |
Owners and trading
Largest institutional holders
Each fund group's share of Kailera Therapeutics. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $159 million in 2 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 20 Apr 2026Buy | Andrew T. KaplanDirector | $134M |
| 20 Apr 2026Buy | Adam KoppelDirector | $25M |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years.